Theranostics 2020, Vol. 10, Issue 24 11063 Ivyspring International Publisher Theranostics 2020; 10(24): 11063-11079. doi: 10.7150/thno.45674 Research Paper CSRP2 suppresses colorectal cancer progression via p130Cas/Rac1 axis-meditated ERK, PAK, and HIPPO signaling pathways Lixia Chen1,2, Xiaoli Long1,2, Shiyu Duan1,2, Xunhua Liu1,2, Jianxiong Chen1,2, Jiawen Lan1,2, Xuming Liu1, Wenqing Huang2, Jian Geng1,2 and Jun Zhou1,2 1. Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 2. Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China. Corresponding authors: Jun Zhou, Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China; Phone: 86-2062789365; E-mail:
[email protected];
[email protected]; or, Jian Geng, Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China; Phone: 86-2061648223; E-mail: geng@ smu.edu.cn. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.03.05; Accepted: 2020.08.21; Published: 2020.09.02 Abstract Metastasis is a major cause of death in patients with colorectal cancer (CRC). Cysteine-rich protein 2 (CSRP2) has been recently implicated in the progression and metastasis of a variety of cancers. However, the biological functions and underlying mechanisms of CSRP2 in the regulation of CRC progression are largely unknown. Methods: Immunohistochemistry, quantitative real-time polymerase chain reaction (qPCR) and Western blotting (WB) were used to detect the expression of CSRP2 in CRC tissues and paracancerous tissues.